TickerFactsScreenerDevelopers

Immunovant, Inc. (IMVT) — Cash & Equivalents

Annual figures by fiscal year, from SEC filings.

2019: $6.99M2020: $100.57M2021: $400.15M2022: $493.82M2023: $376.53M2024: $635.37M2025: $713.97M2026: $902.11M$902.11M
2019Cash & Equivalents (USD)2026
Fiscal YearCash & EquivalentsChange YoY
2026$902.11M+26.4%
2025$713.97M+12.4%
2024$635.37M+68.7%
2023$376.53M-23.8%
2022$493.82M+23.4%
2021$400.15M+297.9%
2020$100.57M+1339.8%
2019$6.99M—